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Our previous work demonstrated that liriodenine, an isoquinoline alkaloid isolated from plant species
of many genera, exhibits a potent cytotoxic effect on various types of human cancer cells. In this study,
we investigated the effect of liriodenine on the growth and viability of human lung cancer cells and
addressed the underlying mechanism of action. We found that liriodenine suppressed proliferation of A549
human lung adenocarcinoma cells in a dose- and time-dependent manner. Flow cytometric analysis showed
that liriodenine blocked cell cycle progression at the G2/M phase. Induction of G2/M arrest by liriodenine
was accompanied by reduction of G1 cyclin (D1) and accumulation of G2 cyclin (B1). In vitro kinase activity
assay demonstrated that the enzymatic activity of the cyclin B1/cyclin-dependent kinase 1 complex was
reduced in liriodenine-treated cells. More importantly, incubation with liriodenine led to activation of
caspases and apoptosis in A549 cells. The apoptosis-inducing activity of liriodenine was more apparent
when cells were cultured under serum-free conditions. Our results indicate that liriodenine exerts potent
anti-proliferative and apoptosis-inducing effects on human lung cancer cells.
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Liriodenine (8H-benzo[g]-1,3-benzodioxolo[6,5,4-de]-
quinolin-8-one), a cytotoxic isoquinoline alkaloid, has been
isolated from plant species of many genera [1]. It has many
biologic activities, including anti-platelet, anti-fungal,
and anti-microbial actions [2–4]. Additionally, it has anti-
arrhythmic efficacy in cardiac tissues and exerts a growth-
inhibitory effect on cultured cancer cells [5–8]. Our previous
study demonstrated that liriodenine has potent cytotoxi-
city against a number of cancer cell lines [9]. However, the
molecular mechanism by which it suppresses cancer cell
proliferation is not totally understood.
Lung cancer is one of the most lethal malignancies in
many countries. In addition, many lung cancer cells show
significant resistance to chemotherapeutic drugs. Therefore,
development of new therapeutic drugs for lung cancer is
clinically important. A recent study has demonstrated that
deregulation of cell cycle control is frequently found in
cancer cells [10]. Three distinct classes of proteins, cyclins,
cyclin-dependent kinases (CDKs), and cyclin-dependent
kinase inhibitors (CDKIs), are involved in the regulation of
cell cycle progression [11,12]. In mammalian cells, G1 cy-
clins (D1, D2, D3, and E) and their partner CDKs control the
G1/S transition of the cell cycle. On the other hand, mitotic
cyclins (mainly B-type cyclins) regulate the progression of
the cell cycle from the G2 to M phase. Cyclins and CDKs are
positive cell cycle regulators, and up-regulation of these
two gene families is frequently found in human cancers. For
example, amplification or over-expression of cyclin D1 or E
has been reported in esophageal, breast, lung, and colon
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cancers [13–16]. Deregulation of CDK2 and 4 was detected
in colon cancer and glioma [17,18]. Conversely, CDKIs are
negative cell cycle regulators, and down-regulation of these
inhibitory proteins is a general phenomenon observed in
human cancers [19,20].
Many natural products and Chinese medicinal herbs
are promising biologic modifiers in cancer treatment. In
the present study, we tested the anti-cancer activity of
liriodenine on lung cancer cells and clarified the molecular
mechanism of action.
MATERIALS AND METHODS
Drug and agents
Liriodenine was prepared according to the procedures
described previously [21]. Propidium iodide (PI) and his-
tone H1 were obtained from Sigma Chemical Co (St Louis,
MO, USA). Annexin-V was obtained from Boehring-
er Mannheim GmbH (Mannheim, Germany). Anti-human
cyclin D1 polyclonal antibody was purchased from
Calbiochem (San Diego, CA, USA). Anti-human cyclin B1
and CDK1 antibodies were from Santa Cruz Biotechnology
Inc (Santa Cruz, CA, USA). Poly(ADP-ribose) polymerase
(PARP) monoclonal antibody was purchased from Clontech
(Palo Alto, CA, USA).
Cell culture
A549 human lung adenocarcinoma cells were cultured in
Dulbecco’s modified Eagle medium/F12 medium, supple-
mented with 10% heat-inactivated fetal calf serum (FCS),
100 µg/mL streptomycin, and 100 IU/mL penicillin in 5%
CO2 at 37°C. Cells were incubated in 10% FCS or serum-free
medium containing various doses of liriodenine for different
time intervals and were harvested for analysis.
Western blot analysis
After various treatments, cells were washed with ice-cold
phosphate-buffered saline (PBS), and harvested in a lysis
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 50 mM sodium fluoride, 1 mM
sodium orthovanadate, 1 mg/mL aprotinin, 2 µg/mL pep-
statin A, and 1 mM phenylmethylsulfonyl fluoride) for
20 minutes on ice, and centrifuged at 12,000g for 20
minutes at 4°C. Protein concentration in cell lysates
was determined using a bicinchoninic acid (BCA) protein
assay kit (Pierce Chemical Company, Rockford, IL, USA).
The lysates (20 µg protein/sample) were subjected to 12%
or 7.5% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE). Proteins were transferred to
nitrocellulose filters, and the blots were blocked overnight
in 5% non-fat milk in TBST buffer (20 mM Tris-HCl, pH
7.4, 137 mM NaCl, and 0.05% Tween 20) at 4°C. The blots
were then probed with various antibodies for 1 hour at
room temperature. After extensive washing in TBST buffer,
peroxidase-conjugated secondary antibody was added
with the blocking buffer for another hour. The blots were
developed using the enhanced chemiluminescence (ECL)
system (Amersham Biosciences UK Ltd, Little Chalfont,
Buckinghamshire, UK) as described previously [22].
Trypan blue exclusion assays
Control or liriodenine-treated cells were harvested after
48 hours’ incubation with drug, and subjected to trypan
blue exclusion assay to evaluate cell viability, as described
previously [23].
Measurement of cell cycle distribution
and apoptosis
Measurement of cell cycle distribution was performed as
described previously [24]. Translocation of phosphatidyl-
serine (PS) from the inner part of the plasma membrane to
the outer layer is found in the early stage of apoptosis and
is a useful biomarker for the detection of apoptosis [25]. We
investigated the appearance of PS on the outer leaflet of cell
membranes by annexin-V staining. In addition, cells were
also stained with PI to differentiate apoptotic cells from
necrotic cells. PI-positive and annexin-V-positive stained
cells (necrotic cells) were gated out in flow cytometric
analysis. Control or liriodenine-treated cells were washed
with ice-cold buffer (10 mM HEPES/NaOH, pH 7.4, 140
mM NaCl, 5 mM CaCl2) and pelleted by centrifugation at
400g for 10 minutes. Cell pellets were fixed in 4% parafor-
maldehyde and resuspended in 100 µL of staining solu-
tion (2 µL annexin-V and 2 µL of 50 µg/mL PI in 100 µL
HEPES buffer), and incubated for 10 to 15 minutes at room
temperature in darkness. Annexin-V or PI fluorescence
intensities were investigated using fluorescence-activated
cell sorter (FACSort) flow cytometry (Becton Dickinson,
San Jose, CA, USA), and the results were analyzed using
CellFITTM (Becton Dickinson) software. Ten thousand cells
were evaluated in each sample.
In vitro kinase activity assays
CDK1 was immunoprecipitated from control or liriodenine-
treated cells, and an in vitro kinase assay was performed
according to the procedures of our previous study using
histone H1 as a substrate [24].
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RESULTS
Effect of liriodenine on cell cycle distribution
of lung cancer cells
As shown in Table 1, there were fewer cells in the G0/G1
phase after liriodenine treatment for 24 hours, while the
number of cells in the G2/M phase increased. These results
suggest that liriodenine induces G2/M arrest in A549 cells.
Since cell cycle progression is controlled via periodic chan-
ges in the cyclin level in cells, we investigated whether
liriodenine might modulate the expression of cyclins to
block proliferation of A549 cells. As shown in Figure 1, a
persistent reduction in G1 cyclin (D1) expression was ob-
served in liriodenine-treated cells. This is consistent with
the results of flow cytometric analysis, which indicated that
the number of cells in the G0/G1 phase was reduced after
liriodenine treatment. Conversely, liriodenine induced
accumulation of G2 cyclin (B1) under the same experimental
conditions. The major partner of cyclin B1 in mammalian
cells is CDK1 (or CDC2), so we performed an in vitro kinase
assay to study CDK1 activity. Liriodenine inhibited CDK1
activity in a time-dependent manner (Figure 2). These
results indicate that, although cyclin B1 expression was
increased in liriodenine-treated cells, the enzymatic activity
of the cyclin B1/CDK1 complex was suppressed, leading to
G2/M arrest.
Apoptosis-inducing activity of liriodenine
In addition to growth inhibition, we found that liriodenine
exhibited cytotoxicity on A549 cells. As shown in Table 2,
there was a dose-dependent increase in the number of
dead cells after liriodenine treatment. Additionally, cells cul-
tured under serum-free conditions were more suscepti-
ble to liriodenine treatment. We next addressed whether
liriodenine caused cell death via induction of apoptosis. The number of PI-negative and annexin-V-positive cells
(apoptotic cells) was increased after liriodenine treatment
(Figure 3). Liriodenine treatment at 20 µM and 50 µM cells
caused apoptosis in 67% and 80% of cells, respectively.
We conclude that the cytocidal activity of liriodenine on hu-
man lung cancer cells is mediated mainly via induction of
apoptosis.
To further confirm our conclusion, we studied the
involvement of caspases in liriodenine-induced apoptosis
by investigating the expression and degradation of a nuclear
protein, PARP. This protein is the first identified in vivo
substrate for various caspases; proteolytic cleavage of
PARP from a 116 kDa polypeptide to an 85 kDa fragment
is a typical marker for the onset of apoptosis. As shown
in Figure 4, degradation of PARP was observed in a time-
Table 1. Effect of liriodenine on cell cycle distribution of
A549 human lung cancer cells assayed by flow cytometric
analysis*
Cell cycle distribution, %
G0/G1 S G2/M
Control 50.8 ±  3.2 28.1 ±  2.1 21.1 ±  2.5
2 µM 41.9 ±  4.1 35.9 ±  3.5 22.2 ±  1.8
20 µM 29.1 ±  3.4 36.0 ±  3.5 34.9 ±  1.2
*Cells were cultured in 10% fetal calf serum medium and treated
with liriodenine for 24 hours. Results are expressed as mean ±
standard error (n = 3).
Figure 1. Modulation of the expression of cyclin B1 and D1 by liriodenine
in A549 human lung cancer cells. Cells were cultured in 10% fetal calf
serum medium and incubated with 20 µM liriodenine for different times.
Cells were harvested in a lysis buffer, and equal amounts of cellular
proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and the expressions of cyclin B1 and D1 were examined
by Western blot analysis.
Figure 2. Liriodenine suppresses cyclin B1/cyclin-dependent kinase
(CDK) 1 activity. Cells were cultured in 10% fetal calf serum medium
and incubated with 20 µM liriodenine for different times. Cells were
harvested in a lysis buffer, and equal amounts of cellular proteins were
subjected to immunoprecipitation by CDK1 antibody. The in vitro
kinase assay was performed using histone H1 as substrate.
Cyclin B1
Cyclin D1
Actin
Treatment (hr) 0 12 24 36 48
Histone H1
Treatment (hr) 0 24 48
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dependent fashion in liriodenine-treated A549 cells. These
results support the notion that liriodenine induces caspase
activation and apoptosis in A549 cells.
DISCUSSION
In this study, we provide the first evidence that liriodenine,
an isoquinoline alkaloid isolated from a variety of plant
species, may inhibit proliferation of lung cancer cells via
inhibition of cell cycle progression and induction of apo-
ptosis. The first novel finding is that liriodenine induces
G2/M arrest via inhibition of the kinase activity of the
cyclin B1/CDK1 complex. Regulation of the G2 to M phase
transition of the cell cycle is complicated. In mammalian
cells, cyclin B1 synthesis is increased from the end of the S
phase due to cell cycle-regulated transcription. Cyclin B1
then associates with CDK1 to form a protein complex that
participates in the control of the G2/M phase. However, it
should be noted that the cyclin B1/CDK1 complex is not
active, and the enzymatic activity of this complex is regulated
by a number of phosphorylation and dephosphorylation
events. Phosphorylation of threonine 161 is required for the
activation of the cyclin B1/CDK1 complex and is mediated
by CDK activating kinase [26]. Moreover, dephosphorylation
of two negative regulatory sites, threonine 14 and tyrosine
15, by CDC25 protein phosphatase is also needed for cyclin
B1/CDK1 activation [27,28]. Some drugs or apoptotic stimuli
may inhibit cyclin B1 expression and CDK1 activity to
induce G2/M arrest [29,30]. On the contrary, other external
signals may stimulate cyclin B1/CDK1 activity to trigger
G2/M arrest [31,32]. Our current results demonstrate that
Table 2. Cytotoxic effect of liriodenine on A549 human lung cancer cells evaluated by trypan blue exclusion assay*
10% FCS Serum-free
24 hr, n = 3 48 hr, n = 3 24 hr, n = 3 48 hr, n = 3
Control 3.8% 3.7% 5.5% 7.4%
2 µM 7.8% 12.9% 14.6% 29.0%
20 µM 22.7% 33.3% 32.9% 73.8%
50 µM 30.2% 42.9% 76.5% 82.5%
*Results are expressed as the mean of two independent experiments, and are shown as the percentage of dead cells.
Figure 3. Induction of apoptosis by liriodenine. Cells were cultured in
serum-free medium and incubated with 50 µM liriodenine for 48 hours
and then harvested. Annexin-V staining shows apoptotic cells. A typical
figure for flow cytometric analysis is shown.
Figure 4. Induction of poly(ADP-ribose) polymerase (PARP) degradation
by liriodenine. Cells were cultured in serum-free medium and incubated
with 50 µM liriodenine for different times. Equal amounts of cellular
proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and PARP degradation from its native form (116 kDa)
to the degraded form (85 kDa) was detected by Western blot analysis.
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α-tubulin
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cyclin B1 accumulated after liriodenine treatment. However,
the kinase activity of the cyclin B1/CDK1 complex was
potently inhibited. It is possible that liriodenine may affect
the phosphorylation and dephosphorylation of this protein
complex to induce G2/M arrest. Further work is needed to
clarify this issue.
Another critical finding of this study is that liriodenine
may induce caspase activation and apoptosis in human
lung cancer cells. Apoptosis is an evolutionarily conserved
process by which cells systematically inactivate and degrade
their own structural and functional components to complete
their own demise. It is activated by different extracellular
stimuli through a genetically defined program. Apoptosis
may be divided into three distinct stages: commitment, in
which cells receive a potentially lethal apoptotic stimulus
and become irreversibly committed to death; execution,
during which the major structural changes occur; and
clearance, when cellular remnants are removed by pha-
gocytosis. Since cells that have undergone apoptosis are
recognized and removed by macrophages without induction
of a severe inflammatory reaction, agents that can speci-
fically activate the apoptotic signaling pathways in can-
cer cells are expected to be ideal anti-tumor agents. Accor-
ding to our results, liriodenine could effectively trigger
caspase activation and PARP degradation and induce
apoptosis in A549 lung cancer cells. These results sug-
gest that liriodenine may be useful for the treatment or
chemoprevention of lung cancer.
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